Coenzyme Q10 (Ubiquinol)
Also known as CoQ10 · ubiquinol · ubiquinone · coenzyme Q10
Research profile
Clinically supported13 key studies reviewed
729 human trials & reviews
15,235 papers on PubMed
Clinical evidence
What the research shows
CoQ10 reliably raises blood CoQ10 levels. Its best clinical evidence is in heart failure, where one 420-patient trial (Q-SYMBIO) found fewer major cardiac events, although a Cochrane review still calls the evidence inconclusive overall. A meta-analysis of 13 RCTs found a small-to-moderate reduction in fatigue. Results for statin muscle pain conflict across meta-analyses, the best-designed trial was null, and Cochrane found no meaningful effect on blood pressure.
Adults with fatigue who want a low-risk trial, statin users with muscle symptoms (evidence mixed), and people with heart failure only under cardiologist supervision as an add-on.
The research is clear: ingredients deliver most when your body actually needs them. That’s why AXEL maps your terrain first, then builds a regimen around you.
Discover your terrainSafety & good-to-know
- Generally well tolerated; only one GI adverse event among 602 CoQ10-treated participants in the fatigue meta-analysis. PubMed 36091835
- In a warfarin cohort, CoQ10 use was linked to self-reported bleeding (OR 3.69). CoQ10 has a vitamin-K-like structure and may change INR, so warfarin users should monitor. PubMed 17723077
Every AXEL regimen can be reviewed by a physician in a consultation.
The studies (13)
Comparative effectiveness of dietary supplements in dilated cardiomyopathy: a systematic review and network meta-analysis.
Network meta-analysis · Dilated cardiomyopathy · n = 14 RCTs, 1,259 · CoQ10 90–150 mg/d and other supplements · Various
CoQ10 at 150 mg/day ranked best for ejection fraction (MD +11.3%), but the trials were mostly small, open-label Chinese studies, and certainty was low to very low.
Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis.
Meta-analysis of RCTs · Statin users with muscle symptoms · n = 7 RCTs, 389 · 100–600 mg/day · 30–90 days
A modest reduction in pain intensity (WMD -0.96, 95% CI -1.88 to -0.03). Four trials were positive and three were null.
Effectiveness of Coenzyme Q10 Supplementation for Reducing Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Meta-analysis of RCTs · Healthy and diseased adults · n = 13 RCTs, 1,126 · Various · Various
Fatigue was reduced (Hedges' g -0.398, 95% CI -0.641 to -0.155), with greater effect at higher dose and longer duration. Adverse events were minimal.
Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials.
Meta-analysis of RCTs · Statin users with muscle symptoms · n = 12 RCTs, 575 · Various · Various
CoQ10 reduced muscle pain (WMD -1.60), weakness, cramp and tiredness, with no change in creatine kinase.
The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial.
RCT · Moderate–severe chronic heart failure · n = 420 · 100 mg three times daily (300 mg/day) ubiquinone vs placebo, on top of standard therapy · 2 years
No change in short-term endpoints at 16 weeks. Major cardiac events: 15% vs 26% (HR 0.50, 95% CI 0.32–0.80). Cardiovascular mortality 9% vs 16%; all-cause mortality 10% vs 18%; fewer heart-failure hospitalisations.
Coenzyme Q10 for heart failure.
Cochrane review · Heart failure · n = 11 RCTs, 1,573 · Various doses · Various
CoQ10 probably reduces all-cause mortality (RR 0.58; one study) and heart-failure hospitalisation (RR 0.62). Effects on ejection fraction and exercise were very uncertain. The authors conclude there is no convincing evidence to support or refute its use.
Coenzyme Q10 supplementation increases blood concentrations but shows limited and inconsistent effects on exercise performance: a systematic review and meta-analysis.
Meta-analysis of RCTs · Healthy adults · n = 24 studies · Various · Acute and chronic
Blood CoQ10 rose consistently, but performance effects were small and unstable (very low to low certainty). There was a suggestion of less subjective fatigue.
The effect of statin treatment on circulating coenzyme Q10 concentrations: an updated meta-analysis of randomized controlled trials.
Meta-analysis of RCTs · Statin users · n = 12 RCTs, 1,776 · Statins vs placebo · Various
Statins lowered circulating CoQ10 (SMD -2.12), regardless of statin type or intensity.
Full research notesOverview, research in progress and study doses
Further research
- Heart failure, alongside standard care (research). In Q-SYMBIO (420 patients with moderate–severe heart failure, 100 mg three times daily for 2 years), major cardiac events were 15% vs 26% (HR 0.50, 95% CI 0.32–0.80), and all-cause mortality was 10% vs 18%. The 2021 Cochrane review rates the mortality benefit moderate-quality, based on that single trial, and still calls the overall evidence inconclusive. PubMed 25282031PubMed 35608922
- Supports mitochondrial energy production / reduces fatigue. In a meta-analysis of 13 RCTs (1,126 people), CoQ10 reduced fatigue scores (Hedges' g -0.40), with larger effects at higher doses and longer use. In healthy adults the effects on exercise performance were small and inconsistent (low certainty). PubMed 36091835PubMed 41457257
- Statin-associated muscle symptoms (research). Meta-analyses disagree: two found less muscle pain (2018 and 2025), while one found no clear benefit (2020). The most rigorous RCT, using 600 mg ubiquinol in patients whose statin muscle pain was confirmed by rechallenge, found no benefit. PubMed 30371340PubMed 41158831PubMed 32179207PubMed 25545331
- Blood pressure. The Cochrane review (moderate-quality evidence; 2 pooled RCTs, n=50) found no significant effect on systolic BP (-3.68 mmHg, CI -8.86 to 1.49) or diastolic BP. PubMed 26935713
- Ubiquinol is better absorbed than ubiquinone. In a crossover study in older adults, ubiquinol capsules were not significantly better absorbed than standard ubiquinone (1.7-fold, CI 0.9–3.1). Absorbed CoQ10 circulates mainly as ubiquinol whichever form is taken. PubMed 32188111
Where the research is still limited
- No clinically meaningful blood-pressure reduction in primary hypertension (Cochrane).
- Did not reduce confirmed statin myalgia in the best-designed RCT.
- No reliable improvement in exercise performance in healthy adults.
- It is not a treatment for heart failure on its own; Q-SYMBIO tested it on top of standard medical therapy.
Study doses
Trials used 100–600 mg/day (Q-SYMBIO 300 mg/day; statin trials 100–600 mg), and the fatigue meta-analysis found a dose-response. The Lipo® CoQ10 Drop provides 100 mg per 1 ml daily serving, the lower end of trial dosing.